Intravenous recombinant tissue plasminogen activator therapy for ischemic stroke patients over 80 years old: a propensity score matched analysis from the Fukuoka Stroke Registry

被引：0
|
作者：
Matsuo, R. [1 ]
Kamouchi, M. [1 ]
Hata, J. [1 ]
Wakisaka, Y. [1 ]
Kuroda, J. [1 ]
Ago, T. [1 ]
Kitazono, T. [1 ]
机构：
[1] Kyushu Univ, Fukuoka 812, Japan
来源：
CEREBROVASCULAR DISEASES | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [21] Recombinant Tissue-Type Plasminogen Activator Plus Eptifibatide Versus Recombinant Tissue-Type Plasminogen Activator Alone in Acute Ischemic Stroke Propensity Score-Matched Post Hoc Analysis
    Adeoye, Opeolu
    Sucharew, Heidi
    Khoury, Jane
    Tomsick, Thomas
    Khatri, Pooja
    Palesch, Yuko
    Schmit, Pamela A.
    Pancioli, Arthur M.
    Broderick, Joseph P.
    STROKE, 2015, 46 (02) : 461 - 464
  • [22] Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: Initial Israeli experience
    Schwammenthal, Y
    Drescher, MJ
    Merzeliak, O
    Tsabari, R
    Bruk, B
    Feibel, M
    Hoffman, C
    Bakon, M
    Rotstein, Z
    Chapman, J
    Tanne, D
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2004, 6 (02): : 70 - 74
  • [23] In-hospital outcomes of intravenous recombinant tissue plasminogen activator treatment for acute ischemic stroke in patients aged >80 years: Findings from the Chinese Stroke Center Alliance
    Jiang, Yingyu
    Wang, Chunjuan
    Gu, Hongqiu
    Zhou, Qi
    Jiang, Yong
    Li, Zixiao
    Wang, Yongjun
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2025, 34 (01):
  • [24] Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? The Calgary experience
    Simon, JE
    Sandler, DL
    Pexman, JHW
    Hill, MD
    Buchan, AM
    AGE AND AGEING, 2004, 33 (02) : 143 - 149
  • [25] Analysis of the risk of hemorrhagic complications in acute ischemic stroke patients with microbleeds after intravenous recombinant tissue plasminogen activator therapy
    Takahashi, Y.
    Morihara, R.
    Narai, H.
    Omori, N.
    Manabe, Y.
    INTERNATIONAL JOURNAL OF STROKE, 2014, 9 : 57 - 58
  • [26] EFFECTIVENESS OF INTRAVENOUS RECOMBINANT PLASMINOGEN ACTIVATOR TREATMENT IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE AGED OVER 80 YEARS: A RETROSPECTIVE COHORT STUDY
    Zhong, W.
    Huang, Y.
    Gong, X.
    Chen, Y.
    Chen, Z.
    Jin, H.
    Yan, S.
    Huang, L.
    Yuan, C.
    Lou, M.
    INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 147 - 148
  • [27] CIRCADIAN VARIATION OF THE EFFICACY OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR IN PATIENTS WITH ACUTE ISCHEMIC STROKE
    Kim, J.
    Lee, S.
    SLEEP, 2018, 41 : A23 - A24
  • [28] CIRCADIAN VARIATION OF EFFICACY OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR IN PATIENTS WITH ACUTE ISCHEMIC STROKE
    Lee, S.
    Kim, J. H.
    INTERNATIONAL JOURNAL OF STROKE, 2018, 13 : 116 - 116
  • [29] A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset
    Balogun, Ibrahim O.
    Brown, Aaron
    Bertoni, Miguel
    Webb, Thomas
    Hargroves, David
    Pullicino, Patrick
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (08): : 1843 - 1850
  • [30] Outcome of Japanese Minor Stroke Patients Treated Without Intravenous Recombinant Tissue Plasminogen Activator Within 4.5 Hours After the Symptom Onset ∼Fukuoka Stroke Registry∼
    Fujimoto, Shigeru
    Osaki, Masato
    Kumamoto, Masaya
    Kanazawa, Makoto
    Tagawa, Naoki
    Ishitsuka, Takao
    Kitazono, Takanari
    STROKE, 2015, 46
12345